These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 16885550)

  • 1. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
    N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.
    Babenko AP; Polak M; Cavé H; Busiah K; Czernichow P; Scharfmann R; Bryan J; Aguilar-Bryan L; Vaxillaire M; Froguel P
    N Engl J Med; 2006 Aug; 355(5):456-66. PubMed ID: 16885549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylurea receptor 1 mutations that cause opposite insulin secretion defects with chemical chaperone exposure.
    Pratt EB; Yan FF; Gay JW; Stanley CA; Shyng SL
    J Biol Chem; 2009 Mar; 284(12):7951-9. PubMed ID: 19151370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
    Rafiq M; Flanagan SE; Patch AM; Shields BM; Ellard S; Hattersley AT;
    Diabetes Care; 2008 Feb; 31(2):204-9. PubMed ID: 18025408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-sensitive potassium channels--neonatal diabetes mellitus and beyond.
    Sperling MA
    N Engl J Med; 2006 Aug; 355(5):507-10. PubMed ID: 16885555
    [No Abstract]   [Full Text] [Related]  

  • 8. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    Gloyn AL; Pearson ER; Antcliff JF; Proks P; Bruining GJ; Slingerland AS; Howard N; Srinivasan S; Silva JM; Molnes J; Edghill EL; Frayling TM; Temple IK; Mackay D; Shield JP; Sumnik Z; van Rhijn A; Wales JK; Clark P; Gorman S; Aisenberg J; Ellard S; Njølstad PR; Ashcroft FM; Hattersley AT
    N Engl J Med; 2004 Apr; 350(18):1838-49. PubMed ID: 15115830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P; Girard C; Baevre H; Njølstad PR; Ashcroft FM
    Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes.
    Girard CA; Shimomura K; Proks P; Absalom N; Castano L; Perez de Nanclares G; Ashcroft FM
    Pflugers Arch; 2006 Dec; 453(3):323-32. PubMed ID: 17021801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I; de Lonlay P; Polak M
    Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
    Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
    Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy.
    Shah B; Breidbart E; Pawelczak M; Lam L; Kessler M; Franklin B
    J Pediatr Endocrinol Metab; 2012; 25(3-4):353-6. PubMed ID: 22768668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes.
    Nielsen LB; Ploug KB; Swift P; Ørskov C; Jansen-Olesen I; Chiarelli F; Holst JJ; Hougaard P; Pörksen S; Holl R; de Beaufort C; Gammeltoft S; Rorsman P; Mortensen HB; Hansen L;
    Eur J Endocrinol; 2007 Jun; 156(6):663-71. PubMed ID: 17535866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features.
    Proks P; Antcliff JF; Lippiat J; Gloyn AL; Hattersley AT; Ashcroft FM
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17539-44. PubMed ID: 15583126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
    Kim MS; Kim SY; Kim GH; Yoo HW; Lee DW; Lee DY
    J Korean Med Sci; 2007 Aug; 22(4):616-20. PubMed ID: 17728498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
    Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
    Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications.
    Tammaro P; Flanagan SE; Zadek B; Srinivasan S; Woodhead H; Hameed S; Klimes I; Hattersley AT; Ellard S; Ashcroft FM
    Diabetologia; 2008 May; 51(5):802-10. PubMed ID: 18335204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
    Gribble FM; Tucker SJ; Seino S; Ashcroft FM
    Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.